Nicholas Mitsiades

Baylor College of Medicine — United States

Medicine · Health Sciences

77h-index24.1kcitations471works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(90), AI in cancer detection(79), Radiomics and Machine Learning in Medical Imaging(77), Multiple Myeloma Research and Treatments(55), Cancer, Lipids, and Metabolism(43)

Publications467 total

Detecting hidden threats using longitudinal liquid biopsies
2025Open Access
Neoadjuvant niraparib in men with DNA repair gene deficient clinically localized prostate cancer: Clinical and molecular results from a phase 2 investigator-initiated trial.
Journal of Clinical Oncology·2025· 1 cited
Fragmentation landscape of cell-free DNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by race.
Journal of Clinical Oncology·2025
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer
Endocrine Related Cancer·2025Open Access
MP08-14 SHARED INCIDENCE OF BLADDER AND LUNG CANCER: ANALYSIS OF THE SEER DATABASE
The Journal of Urology·2025
IP21-06 GERMLINE GENETIC TESTING FOR MEN WITH PROSTATE CANCER: REGIONAL COMPARISON WITH THE 2024 ASCO GUIDELINES
The Journal of Urology·2025
MP07-01 NEOADJUVANT NIRAPARIB IN MEN WITH DNA REPAIR GENE DEFICIENT CLINICALLY LOCALIZED PROSTATE CANCER: RESULTS FROM A PHASE 2 INVESTIGATOR-INITIATED TRIAL
The Journal of Urology·2025
Figure S5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
Figure S3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
Figure S1 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
Figure S2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
Figure S1 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
Figure S2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
Figure S4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
Figure S5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
Figure S4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
Figure S3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
Development of an ex-vivo platform to model immunotherapy in kidney cancer.
Journal of Clinical Oncology·2025
Targeting the soluble epoxide hydrolase (sEH) enzyme to relieve painful docetaxel-induced peripheral neuropathy.
Journal of Clinical Oncology·2025
Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors
Acta Pharmaceutica Sinica B·2025· 7 citedOpen Access
page 1 of 24Next →

Frequent Co-authors

Kenneth C. Anderson(32), Teru Hideshima(26), Constantine S. Mitsiades(25), Nikhil C. Munshi(25), Dharminder Chauhan(24), Paul G. Richardson(21), Vassiliki Poulaki(13), Robert Schlossman(9), Klaus Podar(9), Steven P. Treon(8), Masaharu Akiyama(8), Constantine Mitsiades(7), Toshiaki Hayashi(6), Reshma Shringarpure(6), Cristian Coarfa(5), Marie Joseph(4), Towia A. Libermann(4), Guilan Li(4), Antonia M. Joussen(4), Anthony P. Adamis(4)